Innovative Treatment of Cancer by Selective Protection of Histones from Methylation. The goal of the iSELECT-project is to develop novel inhibitors of Lysin-Methyltransferases (KMT) deregulated in cancer. This will be achieved by an innovative approach combining screening of target family-centric compound libraries against a set of KMTs and multifactorial cellular phenotypic testing. (bron: Eurostars website, projecten database) (bron: www.eurekanetwork.org/project-search)
